Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Millan

Showing results (241-250 of 496) with videos related to

Pageof 50
Sort By:
Acta Leprologica|July 1, 1987
[Anti-BCG antibody titers in healthy and leprous Africans. Value of an indirect immunoperoxidase test]G Agius, E Baillargeau, S Ranger, et al.
Acta Leprologica|January 1, 1986
[The value of electromyographic studies in leprosy]M Ndiaye-Niang, M Diagne, I P Ndiaye, et al.
Brain Research|June 17, 1982
The influence of selective adeno- and neurointermedio-hypophysectomy upon plasma and brain levels of beta-endorphin and their response to stress in ratsR Przewłocki, M J Millan, C Gramsch, et al.
European Journal of Pharmacology|May 30, 1997
Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamineV Audinot, S Lochon, A Newman-Tancredi, et al.
British Journal of Pharmacology|February 7, 2018
Corticotropin-releasing factor receptor 2-deficiency eliminates social behaviour deficits and vulnerability induced by cocaineNadège Morisot, Romain Monier, Catherine Le Moine, et al.
British Journal of Pharmacology|March 1, 1997
Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635A Newman-Tancredi, C Conte, C Chaput, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 4, 2015
Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disordersMark J Millan, Guy M Goodwin, Andreas Meyer-Lindenberg, et al.
Journal of Neurochemistry|October 11, 2003
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropiniroleRoberto Maggio, Marco Scarselli, Francesca Novi, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agentsA Newman-Tancredi, V Audinot, C Chaput, et al.
Neuropharmacology|April 1, 1997
Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometryA Newman-Tancredi, C Conte, C Chaput, et al.
Pageof 50

Showing results (241-250 of 496) with videos related to

Sort By:
Pageof 50
Acta Leprologica|July 1, 1987
[Anti-BCG antibody titers in healthy and leprous Africans. Value of an indirect immunoperoxidase test]G Agius, E Baillargeau, S Ranger, et al.
Acta Leprologica|January 1, 1986
[The value of electromyographic studies in leprosy]M Ndiaye-Niang, M Diagne, I P Ndiaye, et al.
Brain Research|June 17, 1982
The influence of selective adeno- and neurointermedio-hypophysectomy upon plasma and brain levels of beta-endorphin and their response to stress in ratsR Przewłocki, M J Millan, C Gramsch, et al.
European Journal of Pharmacology|May 30, 1997
Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamineV Audinot, S Lochon, A Newman-Tancredi, et al.
British Journal of Pharmacology|February 7, 2018
Corticotropin-releasing factor receptor 2-deficiency eliminates social behaviour deficits and vulnerability induced by cocaineNadège Morisot, Romain Monier, Catherine Le Moine, et al.
British Journal of Pharmacology|March 1, 1997
Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635A Newman-Tancredi, C Conte, C Chaput, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 4, 2015
Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disordersMark J Millan, Guy M Goodwin, Andreas Meyer-Lindenberg, et al.
Journal of Neurochemistry|October 11, 2003
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropiniroleRoberto Maggio, Marco Scarselli, Francesca Novi, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agentsA Newman-Tancredi, V Audinot, C Chaput, et al.
Neuropharmacology|April 1, 1997
Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometryA Newman-Tancredi, C Conte, C Chaput, et al.
Pageof 50